Special issue call for papers:
Combination gene and cellular immunotherapies


Submissions due: August 1, 2021

Submit
Immune effector cells, oncolytic viruses, immunomodulatory antibodies, and gene therapies paved the way for a new therapeutic strategy for cancers. In the clinic, with increasing confidence in safety and toxicity management, investigators are combining therapeutic agents to enhance anti-tumor efficacy, prolong functional persistence, and address potential resistance mechanisms. Preclinical and clinical studies are investigating strategies to overcome complex tumor immune microenvironments to achieve tumor eradication, including multiple-gene editing, varying routes of therapeutic administration, and combinations of novel agents to improve treatment responses. These combination gene and cellular immunotherapies pose exciting regulatory challenges to the field—interpreting toxicities and efficacy and ascribing them to individual agent. In this special issue, we will highlight these advances—preclinical, clinical, and regulatory. In addition, we will include focused commentary of high-impact publications and expert reviews, both invited and submitted.

This special issue of Molecular Therapy—Oncolytics will be guest edited by Prasad S. Adusumilli and Saul Priceman and will feature a set of comprehensive review and original articles written by leading experts in combination gene and cellular immunotherapy.

Topics
  • Cell-based immunotherapy combinations (CAR, TCR, TILs, NK)
  • Oncolytic virus-based combination immunotherapy
  • Gene-editing combinations
  • BiTES
  • Preclinical models
  • Clinical assessment and regulatory (toxicity) issues of combination therapies
  • Preclinical models and assays (mouse, organoid, culture systems)
Article Types
  • Original research articles
  • Brief commentary on high-impact combination immunotherapy publications
  • Review articles
  • Opinion editorials (op-eds)
  • Articles reviewing assays, reagents, and methods
Submissions due: August 1, 2021

Submit
 
 

Guest Editors

Prasad S. Adusumilli
Memorial Sloan Kettering Cancer Center, USA
 
Saul Priceman
City of Hope, USA